Common Reasons for Deficiencies in Overseas Registration of Sterilization and Disinfection Equipment

Deficiency requests during overseas registration of sterilization and disinfection equipment are rarely caused by a single factor. They typically arise from a combination of product classification, technical documentation, validation evidence, labeling and instructions for use, quality management system, local agent, and post-market maintenance. Companies should first determine whether the target country regulates the device as a medical device, then confirm the risk class and the applicable registration pathway, avoiding the use of an inappropriately low-risk route.

Key Summary

Deficiency requests in overseas registration of sterilization and disinfection equipment are usually the combined result of product classification, technical documentation, validation evidence, labeling, quality management system, local agent, and post-market maintenance issues. Common reasons include unclear intended purpose, incomplete standards application, insufficient biocompatibility evaluation, incomplete sterilization validation and shelf-life data, missing software lifecycle documentation, labeling and instructions not meeting local language or symbol requirements, inconsistency between the quality management system certificate and the registration applicant, non-compliant local agent authorization documents, and unclear provisions for certificate control and change notifications.

Existing NMPA, CE, FDA, or ISO 13485 documentation can be reused, but must be locally adapted to the target country's regulatory requirements. Companies should establish a core technical documentation library and systematically verify the differing requirements across GHWP member states and countries in Southeast Asia, the Middle East, and Latin America. This approach fundamentally reduces deficiency rounds and lowers registration timelines and costs.

Applicable Scenarios and Core Issues

Sterilization and disinfection equipment covers a wide range of products, including steam sterilizers, ethylene oxide sterilizers, hydrogen peroxide low-temperature plasma sterilizers, ultraviolet disinfection devices, and medical washer-disinfectors. Regulatory boundaries differ by country: some are regulated as medical devices, some as active medical devices, and others may classify specific products as personal protective or public health equipment. Companies often make an error at this first step by filing under the wrong registration pathway, directly leading to deficiencies.

The core issue is that companies fail to align the product's actual composition with the regulatory intended purpose. For example, if a device intended for hospital surgical instrument sterilization is also claimed for laboratory or industrial use, regulators in different regions will require additional validation data. Another common issue is submitting only the main unit and omitting separate registration requirements for accessories, software, sensors, or connecting parts.

When evaluating the applicable scenario, companies must answer three key questions: Who is the intended user? Is the use setting a hospital, clinic, laboratory, or home care environment? Does the device contact the human body or sterile medical devices? Does it emit energy or include software? These answers directly determine the regulatory classification, reviewing authority, and deficiency requirements. Only by clearly defining the applicable scenario can a company determine which documentation needs to be compiled.

Registration Decision Logic

Step 1: Determine whether the product falls within the target country's medical device regulatory scope. Many sterilization and disinfection devices are regulated as medical devices in some countries and as industrial products in others. For example, surgical instrument sterilizers are typically classified as Class II or IIa, while ultraviolet air disinfection equipment may be classified as electrical appliances in some countries. If this judgment is incorrect, all subsequent documentation becomes invalid.

Step 2: Determine the risk class and registration pathway. Taking GHWP member states as an example, most countries adopt risk classification systems similar to A, B, C, and D. Sterilization and disinfection equipment mostly falls into Class B or C, while a small number of devices that contact tissue or have higher risk may be Class D. The risk class determines whether clinical trials are required, whether quality management system audits are necessary, and whether local testing is mandatory. Companies should not simply copy the CE classification; they must consult the target country's classification rules.

Step 3: Determine the applicant entity. Most countries require a local certificate holder, agent, or authorized representative to submit the application; the manufacturer cannot directly act as an overseas applicant. Companies must confirm the scope of the agreement with the agent, including certificate control, change notification, post-market surveillance, and renewal obligations. A missing valid agency agreement or an agent whose qualifications do not meet requirements is a high-frequency deficiency item.

Step 4: Evaluate whether existing NMPA, CE, FDA, ISO 13485, MDSAP, or other market documentation can be reused. Reuse is not direct translation; a gap analysis must be performed. For example, the validation items required by Chinese domestic disinfection product technical guidance may be one fewer than the target country's requirement for a durability test, and a CE risk management report may need to be supplemented with epidemiological data from the target country or local standards.

Step 5: Confirm the registration document list, including technical documentation, performance validation, risk management, clinical evaluation or clinical evidence, labeling and instructions, local agent, authorized representative, and post-market maintenance requirements. Companies should break down these requirements into specific evidence items and check each for gaps. Many deficiencies occur not because the company lacks raw data, but because the report format does not meet the local template or was not issued by a qualified laboratory.

Documentation and Evidence

The core documentation for registration of sterilization and disinfection equipment typically includes four parts: product technical characteristics, safety and performance validation, risk management documents, and labeling and instructions for use. Each part has typical deficiency points.

Product technical characteristics: Provide clear structural diagrams, working principle, material list, specifications, and software version. Common deficiencies include inconsistency in parameters or unspecified materials. For example, if the sterilization chamber material is listed as 'stainless steel' without indicating the grade, regulators will require a specific grade such as 316L or 304, and material certificates.

Safety and performance validation: This is the most frequent area for deficiencies. Validation for sterilization equipment should at least include sterilization efficacy, load temperature uniformity, drying efficacy, residue detection, electrical safety testing, electromagnetic compatibility testing, biological evaluation, and shelf-life validation. Many companies perform only some of these studies, or only conduct factory testing rather than type testing. Deficiency notices will require complete validation reports and raw data.

Risk management documentation: Must follow the ISO 14971 framework and incorporate target country-specific requirements. For example, ethylene oxide sterilizers require additional analysis of residual EO risks to patients and operators, and hydrogen peroxide plasma devices require analysis of leak and low-temperature burn risks. Every hazard identified in the risk assessment must have a corresponding control measure and validation evidence; conclusions alone are insufficient.

Clinical evaluation and clinical evidence: Not all sterilization and disinfection devices require this. However, if the product is claimed to process implants or high-risk medical devices, regulators may require literature evaluation, comparative device analysis, or clinical data. Companies should confirm the exemption conditions and required evidence level in advance.

Labeling and instructions for use: Must comply with the target country's language, font, and symbol requirements. Common deficiencies include missing warning labels, no local language version, no operator protection instructions, or unclear statements about single-use versus reusable status. The label's shelf life and sterilization status markings are also frequent issues.

Common Errors

• Incorrect product classification, using a low-risk pathway for a high-risk device, causing rejection and significant delay when reclassified.
• Directly translating NMPA or CE reports without checking whether the standard versions and test methods are recognized by the target country.
• The quality management system certificate's registered address is inconsistent with the applicant entity, or the ISO 13485 certificate scope does not cover the design and production of sterilization and disinfection equipment.
• The sterilization validation report's device model, dimensions, and load pattern do not match the registered model, making it impossible for the reviewing authority to confirm coverage.
• The risk management report lists hazards but does not provide residual risk evaluation after risk reduction or establish acceptance criteria.
• Missing complete software lifecycle documentation, or unclear correlation between software version and medical device version.
• The local agent agreement does not include sufficient responsibilities such as post-market surveillance, adverse event reporting, change notification, and certificate maintenance.
• Labeling and instructions use mixed languages, key warning information is not highlighted, or symbols do not reference applicable standards.

Company Preparation Checklist

• Establish a product family and model difference comparison table, clearly identifying the differences between the declared model and existing models to avoid unclear validation report coverage.
• Prepare product classification justification documents, including the target country's classification rules, intended purpose statement, and classification decision trail.
• Compile an inventory of existing certificates and test reports, noting validity period, standard version, laboratory qualification, and scope.
• Systematically verify sterilization efficacy validation, sterilant performance, load temperature uniformity, moisture residue, material compatibility, and residue detection reports.
• Improve risk management documentation, ensuring full traceability from risk analysis and risk evaluation to risk control, with assigned responsibilities.
• Review labels, instructions for use, and packaging, confirming language, symbols, warnings, and dimensions meet target country requirements.
• Confirm the local agent or authorized representative's qualification documents, notarized powers of attorney, and agreement validity, and clarify obligations for changes and renewal.
• Prepare a post-market surveillance plan and periodic safety update report templates, including adverse event collection, complaint handling, and risk signal monitoring procedures.

AIMEILI Regulatory Interpretation and Business Impact

The most common misjudgment is believing that a CE certificate is sufficient for quick overseas registration. In fact, a CE certificate only reflects European requirements and does not cover the specific requirements of GHWP member states. Many Southeast Asian and Middle Eastern countries will re-review test reports, and some even require local performance testing. If a company does not conduct a standard gap analysis at an early stage, deficiencies are almost inevitable.

At the beginning of a project, companies should conduct a regulatory scan of the target countries, clarify classification, registration pathway, technical file format, language requirements, and agent responsibilities, and then prioritize the preparation of documentation. Investing a small cost in a gap analysis early will save more time and money than repeated deficiency responses.

Reusable documentation includes: ISO 13485 system certificates, product structure and principle, basic electrical safety and EMC test data, core sterilization efficacy validation data, and the ISO 14971 risk management framework. Documentation that must be localized includes: classification justification, clinical evaluation or literature basis, language versions of labeling and instructions, local agent agreements, post-market surveillance plans, and renewal documentation.

The local agent and certificate control are critical. Many deficiencies are caused by the agent failing to respond promptly to regulatory comments or by the agent agreement lacking change notification authority. Companies should ensure the agent has local regulatory competence and clearly specify in the agreement that the certificate remains under the control of the manufacturer or the designated entity.

For multi-country registration, establish a 'core technical documentation library' that separates common data from country-specific data. Each registration then involves only incremental localization, rather than recompiling the entire set of files. This significantly reduces rework and deficiency risk and is key to controlling multi-country registration costs.

Common Follow-up Questions

Can Chinese GB standards and test reports be used directly for registration in Southeast Asia?

No, they cannot be used directly. Most Southeast Asian countries recognize ISO standards or international standards adopted by their own regulations, but not necessarily GB standards. Companies should prioritize international standards such as ISO 11135, ISO 11138, ISO 14937, and IEC 61010 for the design of validation studies. Before testing, confirm that the laboratory is ISO 17025 accredited and recognized by the target country. Chinese test reports can be used as reference, but additional difference testing or a method equivalence argument is usually required.

How should the validity of sterilization validation reports be managed? Can data be shared between new and existing models?

Sterilization validation can be divided into design validation and process qualification. Design validation typically has no fixed expiry date, but if the referenced standard is updated, regulators may require additional tests for the new requirements. Process qualification must be linked to the device's service life and requalification plan. Shared validation data is permissible only if the declared model and the existing model are consistent or covered in terms of structure, materials, sterilizer chamber dimensions, software version, and critical components, and a thorough gap analysis is performed. If load patterns or sterilization cycles differ, supplementary validation is required.

If supplementary materials are incomplete, can an extension or partial submission be requested?

Most countries allow supplemental materials to be submitted within a given deficiency response period, but there are strict limits on the number and total duration of extension requests. Companies should first submit the most critical evidence, such as technical files and risk analysis, and then submit performance validation and quality system documents in batches. At the same time, proactively communicate with the regulatory authority or agent to clarify priorities and avoid delaying the entire registration due to a single issue. A deficiency response is not a restart, but each submission must fully align with the reviewer's comments in formatting and content.

Content Review and Applicability Boundaries

Content prepared by AIMEILI Regulatory Editorial Department; professionally reviewed by AIMEILI Medical Device International Registration Project Team. Source principle: priority is given to official regulatory authorities, international organizations, standard organizations, and public regulatory information; industry media and project experience are used only as supplementary judgment.

This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements, testing conclusions, or legal opinions of the target country's regulatory authorities.

According to the AIMEILI registration practice database, medical device international registration knowledge base, and public regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authorities and the product documentation basis. Published: 2026-08-28 13:21. Updated: 2026-08-28 13:21.